

亞東紀念醫院

NPC

化學治療處方集

2008-08 制定

最近修改日期：2014-05

NPC 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【EPF】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

1. Medically fit patients

Epirubicin 75mg/m², ivd 30mins, D1
Cisplatin 75mg/m², ivd 12hrs, D1
5-FU 800mg/m², iv drip, D2-D5
Repeated cycles every 3 weeks

2. Medically unfit patients

Epirubicin 60mg/m², ivd 30mins, D1
Cisplatin 60mg/m², ivd 12hrs, D1
5-FU 800mg/m², iv drip, D2-D4
Repeated cycles every 3 weeks

【EP-HDFL】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Epirubicin 40 mg/m² ivd 15mins, D1
Cisplatin 60 mg/m² ivd 3hrs, D1
Leucovorin 300 mg/m² ivd 1hr, D1
5-FU 2000 mg/m² ivd 24hrs, D1, 8
Repeated cycles every 3 weeks

【MEPFL】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Mitomycin 8mg/m² ivd 30mins, D1
Epirubicin 60mg/m² ivd 30mins, D1
Cisplatin 60mg/m², ivd 3hrs, D1

NPC 化學治療處方參考集

2008-08 制定 2014-05 最後修定

Leucovorin 50mg/m² ivd 30mins, D8
5-FU 450mg/m² ivd 30mins, D8
Repeated every 3 weeks

【Gemcitabine + Cisplatin】

化療屬性：
 Induction / neoadjuvant
 Concurrent chemoradiotherapy (CCRT)
 Palliative

Gemcitabine 1000mg/m² ivd 30mins D 1, 8
Cisplatin 75mg/m² ivd 3hrs D1
Repeated cycles every 21 days

(*Note: Infusion of Gemcitabine can also be 100 mg/m²/10mins, so called fixed dose infusion rate)

【PF】

化療屬性：
 Induction / neoadjuvant
 Concurrent chemoradiotherapy (CCRT)
 Palliative

1. For medically fit patients

Cisplatin 75 mg/m² IV drip 3hrs, D1
5FU 800 mg/m² IV drip 24hrs, D1-D4
Repeated every 3 weeks

2. For medically unfit patients

Cisplatin 60 mg/m² IV drip 12hrs, D1
5FU 800 mg/m² IV drip 12hrs, D2-D4
Repeated every 3 weeks

(*Note: cisplatin is replaced by carboplatin at AUC=4 for those with impaired renal function)

NPC 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Ifosphamide-Etoposide (IE)】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Ifosphamide 2000 mg/m² ivd 8hrs, qd, D1-D3

Etoposide 80mg/m² ivd 2hrs, qd, D1-D3

Mesna 700mg/m² ivd q8h, D1-D3

Repeated every 3 weeks

【Paclitaxel — Cisplatin】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Paclitaxel 80 mg/m² ivd 1hrs, D1, D8

Cisplatin 35mg/m² ivd 2hrs, D1, D8

Repeated every 3 weeks

【Gemcitabine — Navelbine】

Gemcitabine 1000mg/m² ivd 30mins D 1, 8

Navelbine 20mg/m² ivd 3hrs D1, D8

Repeated every 3 weeks

(*Note: Infusion of Gemcitabine can also be 100 mg/m²/10mins, so called fixed dose infusion rate)

【Gemcitabine — Oxaliplatin】

Gemcitabine 1000mg/m² ivd 30mins D 1

Oxaliplatin 85mg/m² ivd 3hrs D1

Repeated every 2 weeks

(*Note: Infusion of Gemcitabine can also be 100 mg/m²/10mins, so called fixed dose infusion rate)

NPC 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Weekly methotrexate (MTX)】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

1. For medically fit patients :

MTX 100 mg/m² ivd 90mins; D1, D8, repeated every three weeks

2. For medically unfit patients :

MTX 40 mg/m² ivd 30mins, weekly

【Weekly Cisplatin – CCRT】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 35mg/m² IV drip 2hrs, weekly

(For medically unfit patients, cisplatin dose is reduced to 30mg/m²)

【Weekly Carboplatin – CCRT】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Carboplatin (AUC=2) IV drip 1hrs, weekly

[final dose=(GFR+25)*AUC]

【Weekly Cisplatin+MTX – CCRT】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

MTX 40 mg/m² IV drip 30mins, D1

Cisplatin 35 mg/m² IV drip 2hrs, D2

Repeated every week

NPC 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Weekly PFL – CCRT】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 35 mg/m² ivd 2hrs, D1
Leucovorin 50mg/m ivd 30mins, D1
5-FU 500mg/m² ivd 30mins, D1
Repeated every week

References :

1. J Clin Oncol 2005; 19: 4305-4313
2. J Clin Oncol 2003; 21:631-637
3. Cancer 2005;103: 569-75
4. Oral Oncol. 2012;48:1146-51
5. Am J Clin Onco. 2012;35:255-60
6. Ann Oncol. 2009;20:1854-9
7. J Clin Oncol 2001;19: 4305-13
8. Head Neck 2006;28:74-80